The Effect Of IL28B Haplotype On Hepatitis C Virus Infection And Treatment Response
Funder
National Health and Medical Research Council
Funding Amount
$525,576.00
Summary
About 3% of the world population is currently infected with hepatitis C virus (HCV). Most have chronic infection with a high risk for progressive liver fibrosis and subsequent liver cirrhosis and hepatocellular carcinoma. We have recently demonstrated genetic variants of the IL28B gene predict viral clearance with and without treatment after HCV infection. Determining why will impact on the development of new therapies, optimise use of current therapies, and identify patients who may respond to ....About 3% of the world population is currently infected with hepatitis C virus (HCV). Most have chronic infection with a high risk for progressive liver fibrosis and subsequent liver cirrhosis and hepatocellular carcinoma. We have recently demonstrated genetic variants of the IL28B gene predict viral clearance with and without treatment after HCV infection. Determining why will impact on the development of new therapies, optimise use of current therapies, and identify patients who may respond to alternative therapies.Read moreRead less
The Role Of Adiponectin-mediated Nitric Oxide On Portal Hypertension And Liver Fibrosis
Funder
National Health and Medical Research Council
Funding Amount
$526,380.00
Summary
Liver cirrhosis is associated with high portal pressure that can result in severe bleeding and death. Adiponectin, a circulating protein, protects the liver from inflammation and scarring and may reduce portal pressure. We will characterise the mechanisms by which adiponectin induces NO and limits liver damage and determine if adiponectin treatment can reduce portal hypertension and bleeding in liver disease.